News

Eye scans may be helpful tool to distinguish NMOSD, MS in patients

Using noninvasive eye scans may help clinicians to determine if patients — particularly those in early disease stages — have neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), both immune system disorders. That’s according to a review of published studies that together reveal that people with NMOSD…

Ultomiris found safe, effective in complex NMOSD cases: Study

The infusion therapy Ultomiris (ravulizumab-cwvz) safely and effectively reduces the risk of a relapse in complex cases of neuromyelitis optica spectrum disorder (NMOSD) and may be combined with rituximab for short periods, a case series study shows. For four NMOSD patients at a hospital in Fujiyoshida, Japan, Ultomiris…

Bio-Thera to file for BAT4406F’s approval for NMOSD in China

Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…

Impaired sleep common among NMOSD patients, study finds

Most people with neuromyelitis optica spectrum disorder (NMOSD) have impaired sleep quality and architecture — an individual’s cyclical sleep pattern, involving different stages — relative to healthy people, according to a new study from researchers in India. NMOSD patients were also found to have reductions in the volume of…

NMOSD among autoimmune disease risk factors: Study

People with neuromyelitis optica spectrum disorder (NMOSD) are at a nine times higher risk of developing autoimmune rheumatic diseases, or those affecting the joints, muscles, or connective tissue, a South Korean study found. Connective tissue provides support, connection, and binding for tissues and organs. The findings align with a…

Rituximab, MMF may be effective off-label options for NMOSD: Study

Rituximab and mycophenolate mofetil (MMF) may be the most effective off-label options for neuromyelitis optica spectrum disorder (NMOSD) patients who are unable to access approved therapies, often due to high costs or limited availability, according to a study in China. The study compared the safety and efficacy of four immunosuppressive…

Infection rates lower with Enspryng over other immunosuppressives

Infection rates were consistently lower in adults with neuromyelitis optica spectrum disorder (NMSOD) treated with Enspryng (satralizumab-mwge) over other immunosuppressive therapies, according to long-term data from clinical trials and real-world settings. “This analysis provides reassurance that the [Enspryng] safety profile observed in patients with NMOSD in a clinical…